GSK, RSV and Shingles
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients and potentially bolster GSK’s faltering sales for both vaccines.
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older).
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
Reuters11d
GSK's experimental herpes vaccine fails to meet main goal in trial
Sept 11 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial ...
FiercePharma5d
GSK makes Brooke Shields the star of shingles vaccination push
GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...
kalkinemedia11d
Berenberg Signals GSK's Challenges Are Clearing
GSK PLC, (OTC:GLAXF),has been noted by broker Berenberg, which highlights a potential easing of challenges that have impacted ...
STAT9d
Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target
BARCELONA, Spain — A targeted immunotherapy being developed by the biotech iTeos Therapeutics and GSK delivered promising response rates in patients with a type of lung cancer, propelling the ...
Bloomberg L.P.11d
GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline
GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline GSK could beat Pfizer to market, says chief commercial officer Several drugmakers are betting on mRNA seasonal flu vaccines ...
FierceBiotech10d
GSK's mRNA flu vaccine finally overcomes tricky B strains in phase 2 trial
After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...
STAT12d
Pharmalittle: We’re reading about a Novo weight loss study, a GSK vaccine failure, and more
We hope you have a wonderful day, and please do keep in touch. … An experimental vaccine from GSK for combating herpes failed in an early-stage trial, halting an effort to bring the first shot ...
World Trademark Review18h
Video game filing trends; Supreme Court amicus warnings; Brand Action, GSK, Harley-Davidson, Mattel; and much more
Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.
Yahoo Finance9d
GSK reports positive interim data from mRNA influenza vaccine trial
GSK has reported positive interim results from its Phase II trial of mRNA-based multivalent influenza vaccine candidate, GSK4382276A. The trial, which included 500 participants across two age ...
Joplin Globe4d
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
The proposed trade name remains subject to regulatory approval in other markets. The GSK proprietary AS01 adjuvant system contains ... are at increased risk for LRTD caused by RSV. Please see ...
Down another 6% in a week! So will the GSK share price ever recover?
The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...